Loading...

Enzo Biochem, Inc.

ENZNYSE
Healthcare
Medical - Diagnostics & Research
$0.31
$-0.07(-17.77%)

Enzo Biochem, Inc. (ENZ) Stock Overview

Explore Enzo Biochem, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 62.4/100

Key Financials

Market Cap16.4M
P/E Ratio-0.77
EPS (TTM)$-0.14
ROE-0.39%

AI Price Forecasts

1 WeekN/A
1 Month$0.59
3 Months$0.66
1 Year Target$0.54

ENZ Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Enzo Biochem, Inc. (ENZ) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.54.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.77 and a market capitalization of 16.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
2.72%
2.72%
Profit Growth
$-0.41
228.54%
EPS Growth
$-0.41
59.84%
Operating Margin
-29.86%
60.31%
ROE
-38.85%
228.54%
Dividend Yield
0.00%
Analyst Recommendations data is not available for ENZAnalyst Recommendations details for ENZ are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.

CEO

Kara Cannon

Employees

125

Headquarters

527 Madison Avenue, New York City, NY

Founded

1980

Frequently Asked Questions

;